What is Alector?
Founded in 2013 and headquartered in South San Francisco, California, Alector is at the forefront of developing novel therapeutics for neurodegenerative diseases that disproportionately affect elderly populations. The company's scientific approach centers on understanding the underlying biological mechanisms of these debilitating conditions to create preventative and disease-modifying treatments. Alector's commitment to innovation in this critical area of unmet medical need positions it as a key player in the global health landscape, aiming to significantly improve patient outcomes and quality of life.
How much funding has Alector raised?
Alector has raised a total of $430.5M across 6 funding rounds:
Series C
$32M
Series D
$29.5M
Series E
$133M
Stock Offering
$176M
Debt
$50M
Debt
$10M
Series C (2015): $32M with participation from Mission Bay Capital, Polaris Partners, MRL Ventures Fund, OrbiMed, Topspin Partners, and GV
Series D (2016): $29.5M led by AbbVie, Dementia Discovery Fund, and Amgen Business Development
Series E (2018): $133M supported by Foresite Capital, Section 32, OrbiMed, Amgen Business Development, Deerfield, Mission Bay Capital, Casdin Capital, AbbVie Ventures, Federated Kaufmann Fund, Polaris Partners, Lilly Asia Ventures, MRL Ventures, the Dementia Discovery Fund, Euclidean Capital, New Leaf Venture Partners, GV, and Perceptive Advisors
Stock Issuance/Offering (2019): $176M, investors not publicly disclosed
Debt (2024): $50M backed by Hercules Capital
Debt (2024): $10M with participation from Hercules Capital
Key Investors in Alector
AbbVie
AbbVie Inc. is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines and health solutions that address some of the worlds most complex medical challenges. Their focus spans immunology, oncology, neuroscience, and other areas with significant unmet medical needs.
Foresite Capital
Foresite Capital is a multi-stage investment firm focused on transforming healthcare and life sciences by investing in companies that utilize biology and big data, targeting breakthrough opportunities at the intersection of technology and biotechnology.
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, digital health platforms, diagnostics, and healthcare services.
What's next for Alector?
With the recent influx of major strategic investment, Alector is poised to further advance its research and development programs. The company's focus on neurodegenerative diseases, a challenging yet crucial area of medical science, suggests a strategic expansion of its clinical trials and therapeutic discovery efforts. This latest financing round, following a history of substantial capital raises, indicates strong investor confidence in Alector's scientific vision and its potential to deliver breakthrough treatments. The company is likely to leverage this backing to forge new partnerships, enhance its drug development pipeline, and potentially scale its operations to meet the growing demand for effective neurodegenerative disease interventions.
See full Alector company page
